Ajanta Pharma

Stocks with price-volume breakout: Ajanta Pharma, JBMA, Manappuram Finance

Ajanta Pharma, JBMA Auto and Manappuram Finance have seen strong price action backed by heavy trading volume in Wednesday's trading session.

Ajanta Pharma hits over 5-month high after partnering with Biocon

Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market Semaglutide

Ajanta Pharma signs pact with Biocon to sell semaglutide in 26 countries

Ajanta Pharma has signed an in-licensing pact with Biocon to market semaglutide across 26 countries in Africa, the Middle East and Central Asia, subject to approvals

Ajanta Pharma sets aside ₹1K crore for acquisitions to plug therapy gaps

Pain management, dermatology, nephrology and gynaecology are emerging as key focus areas

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Ajanta Pharma offers growth potential amid US generic challenges: Nuvama

With larger generic companies facing growth challenges in the US in FY27E, Ajanta Pharma, analysts believe, offers a strong investment opportunity, driven by its branded market growth

Ajanta Pharma shares gain 3% on Q2FY26 results, dividend update; details

The dividend, the company said, will be paid on or after November 20, 2025

Ajanta Pharma newly rated 'Buy' at PL Capital; 26% upside seen; check TP

The brokerage analysis suggested that branded generics contributed to 74 per cent of Ajanta Pharma's revenue in FY25 and its branded generics business operates with a healthy OPM of 30 per cent

Tariff worries, Sun Pharma Q1 miss: Why are pharma stocks falling today?

Pharma stocks came under pressure after President Trump announced a 25 per cent tariff rate for Indian exports to the US

Stocks to buy today: InCred Equities picks 21 stocks to 'Add' for June 2025

Looking for the best stocks to buy today? Incred Equities has released its top stock picks for June 2025, recommending 21 stocks to 'Add' across largecap, midcap, and smallcap segments

Buy, sell? These stocks fell up to 12% post Q4 results. Check strategy here

Indus Towers, Godrej Agrovet, Phoenix Mills, Ajanta Pharma and Star Health stocks dropped up to 12% in intra-day deals on Friday; here are the key levels to track on these 5 stocks.

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Ajanta Pharma Q3 results: Net profit increases 11% to Rs 233 crore

Ajanta Pharma on Thursday said its consolidated profit after tax increased by 11 per cent on-year to Rs 233 crore for the third quarter ended December 31, 2024. The drug firm had reported a profit after tax (PAT) of Rs 210 crore in the October-December period of last fiscal. Revenue from operations stood at Rs 1,146 crore in the third quarter compared to Rs 1,105 crore in the year-ago period, Ajanta Pharma said in a regulatory filing. Shares of the company settled 1.64 per cent higher at Rs 2,670.70 apiece on the BSE.

Ajanta Pharma share price zooms 4% as ex-dividend date looms; details here

The uptick comes ahead of the company's ex-dividend date tomorrow, driven by its recent dividend announcement that promises rewards for eligible shareholders

Pharma shares rally; Suven, Granules, Ajanta, Jubilant surge over 5%

Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.

Ajanta Pharma Q1 results: PAT up 18% to Rs 246 cr on robust sales

Ajanta Pharma on Tuesday said its consolidated profit after tax (PAT) increased 18 per cent year-on-year to Rs 246 crore for the June quarter, on account of robust sales across domestic and international markets. The drug firm had reported a profit after tax of Rs 208 crore in the April-June quarter of last fiscal. Revenue from operations rose to Rs 1,145 crore during the quarter under review as against Rs 1,021 crore in the year-go period, Ajanta Pharma said in a regulatory filing. The company said its India sales grew 10 per cent year-on-year to Rs 353 crore in the first quarter. The company's US sales grew 7 per cent to Rs 228 crore in the first quarter of the current fiscal. Shares of Ajanta Pharma ended 3.99 per cent up at Rs 2,524.35 apiece on the BSE.

Ajanta Pharma surges 13% post solid March quarter results, buyback plan

Ajanta Pharma stock price update: The company has fixed May 30, 2024 as the record date to determine the eligible shareholders for buyback

Ajanta Pharma Q4 results: Net profit increases 66% to Rs 203 crore

Ajanta Pharma on Thursday said its consolidated net profit increased 66 per cent to Rs 203 crore in the March quarter, aided by robust sales across domestic and international markets. The drugmaker had reported a net profit of Rs 122 crore in the January-March quarter of the previous fiscal. Revenue from operations rose to Rs 1,054 crore in the fourth quarter of FY24 as compared with Rs 882 crore in the year-ago period, Ajanta Pharma said in a regulatory filing. For the year ended March 31, 2024, the company posted a consolidated net profit of Rs 816 crore as against Rs 588 crore in the 2022-23 fiscal year. Revenue from operations rose to Rs 4,209 crore for FY24 as compared with Rs 3,743 crore in FY23. The company said it distributed Rs 642 crore to its shareholders in the form of dividend in FY24. The drug firm generated a cash flow of Rs 812 crore and, given this financial position, the board of directors has approved the distribution of Rs 351 crore to shareholders in the form

Ajanta Pharma Q2 results: Consolidated profit up 25% at Rs 195 crore

Ajanta Pharma Ltd on Tuesday reported a 24.71 per cent rise in consolidated net profit at Rs 195.3 crore for the second quarter ended September 30, 2023. The company had posted a consolidated net profit of Rs 156.6 crore in the same quarter last fiscal, Ajanta Pharma said in a regulatory filing. Consolidated revenue from operations was at Rs 1,028.44 crore as against Rs 938.10 crore in the year-ago period, it added. Total expenses were marginally lower at Rs 773.8 crore as compared to Rs 775.45 crore in the corresponding period a year ago, the company said. Branded generic business in India sale was at Rs 355 crore as against Rs 314 crore in the same quarter last fiscal, while the total branded generic business sales across geographies was at Rs 743 crore in Q2 as compared to Rs 711 crore in the year-ago period, up 4 per cent, it said. In the US, the generic business posted sales of Rs 237 crore as compared to Rs 185 crore in Q2 last fiscal, up 28 per cent, the company added.

Ajanta Pharma surges 11% in subdued market on healthy business outlook

In the past two months, the stock has surged 35 per cent after it reported a healthy set of numbers for June quarter